Haptoglobin is one of acute phase glycoproteins often used as markers in glycopathology studies. In this work the oligosaccharide structures of haptoglobin from 'healthy' subjects have been studied in detail, taking into consideration the possible dependence of glycosyla tion on the phenotype. About 75% of charged haptoglobin glycans were of biantennary complex structure, and some of them lacked one terminal sialic acid molecule. Triantennary structures made up almost 25% of the charged glycans pool, and highly branched tetrasialylated oligosaccharides did not exceed 1%. The main difference between haptoglobin derived from the sample of pooled 44 sera and from the 2 -2 phenotype individual concerned the relative content of trisialylated oligosaccharide with one 2 -3 linked sialic acid residue. The oligosaccharide profile of haptoglobin derived from serum of a patient suffering from con genital disorder of glycosylation was compared to 'healthy' controls. It was shown, that four main glycans are identical in patient and 'normal' haptoglobins. Some alterations were found in the relative content of mono-, bi-, and trisialylated glycans as well as in the appearance of some tracely abundant oligosaccharides in haptoglobin of the patient with congenital dis order of glycosylation.
Introduction
Biological importance of glycosylation, as well as the significance of its alterations following the pathological events are intensively studied and dis cussed over last years (Dwek, 1998; Wormald and Dwek, 1999; Qasba, 2000; Kim and Varki, 1997; 0rntoft and Vestergaard, 1999; Durand and Seta, 2000) . Recent interest is focused to examine the role of glycan moiety in the functional activity of glycoconjugates as folding-mediating or recogni tion molecules (Qasba, 2000 ; Rudd et a l, 1999; Watson et a l, 1999). On the other hand in some diseases, such as cancer, rheumatoid arthritis and inflamation, altered branching, fucosylation and sialylation of glycans was reported (Kim and Varki, 1997; 0rntoft and Vestergaard, 1999; Dur and and Seta, 2000 such cases modifications of oligosaccharides are considered as secondary markers for the disease, these changes could be potent diagnostic parame ters, and they also can play a significant role in the progression of the disease (0rntoft and Vester gaard, 1999; Krause and Turner, 1999 ; De Graaf et a l, 1993). Altered glycan structures of acute phase proteins are supposed to mediate the interaction of selectins with sialyl-Lewis X epitopes, acting as the immunomodulators (De Graaf et a l, 1993). Inherited disorders in the metabolic pathways of oligosaccharides biosynthesis and degradation is another field of interests, and, among them, the group of congenital disorders of glycosylation (Aebi et a l, 2000) , formerly called carbohydratedeficient glycoprotein (or Jaeken's) syndromes. These disorders result from the deficiency in a sin gle enzyme of the glycosylation pathway. Some de fects were identified in the initial steps of N-glycosylation, namely in the synthesis of GDP-mannose or lipid-linked oligosaccharide precursor, and clasified as CDG type I, subtypes la -Ie (Aebi et a l, 2000; Freeze, 1998 defect was identified in the processing of oligosac charides attached to the polypeptide chain and called CDG type Ha (Schächter and Jaeken, 1999) . In all patients abnormal glycosylation of serum proteins, mainly transferrin, was found (Freeze, 1998; Carchon et al., 1999; Schächter and Jaeken, 1999) . As the result of particular enzyme deficien cies glycoproteins lack some glycan units in CDG type I or one of the glycan antennae in CDG type II. The structure of oligosaccharides attached to polypeptide chain was found to be normal for se rum transferrin in CDG type I (Iourin et al., 1996) . In all CDG I patients substantial glycosylation of glycoproteins still persists, suggesting that some kind of 'bypassing' of the defect is possible (Freeze, 1998) . It was also reported, that the fre quency of different underglycosylated forms of glycoproteins differ among patients, and, probably, particular serum glycoproteins are not affected to the same degree even in the same individual (Stibler et al., 1998). For all these reasons studying glycosylation of glycoproteins other than transfer rin should give new information on the biochemis try of CDG.
The glycosylation of haptoglobin in physiologi cal and pathological conditions has been studied for the last years (K^tnik et al., 1994; K^tnik and Jadach, 1996; Turner et al., 1995; Brinkmanvan der Linden et al., 1998; K^tnik et al., 1996) . Anyway, data on the oligosaccharide structure of healthy human haptoglobin are limited to the 1 -1 phenotype of this glycoprotein (Nilsson et al., 1981) . This phenotype is the most rare one in Polish population.There is also no information if there are any phenotype-dependent variations in oligosaccharide structures. On the other hand, biological and clinical importance of haptoglobin polymorphism was confirmed (Langlois and Delanghe, 1996) . Previously, we have described (Ferens-Sieczkowska et al., 1999) the lack of some glycan chains in haptoglobin isolated from the serum of the only diagnosed so far in Poland patient with congenital disorder of glycosylation. Althoug the genetic defect was not confirmed, the pattern of serum Hp indicated for type I of the disease.
In the current study we report on the structure of sugar chains of haptoglobin isolated from heal thy human sera and from the serum of the CDG patient.
Materials and Methods

Serum samples
Control haptoglobins were isolated from the sera of healthy volunteers. Sample designated 'control-pooled H p' was isolated from the pooled sera of 44 healthy subjects (23-57 years, average 39, median 38); 24 women (23-57 years, average 39.5, median 37) and 21 men (23-50 years, average 39, median 38). Haptoglobin levels in studied sera were comprised within the values ac cepted as 'normal' (0.8-1.6 g/1). Haptoglobin phe notypes were determined in all subjects. Pooled se rum contained 25 samples of Hp 2 -1 phenotype (12 women and 13 men), 15 samples of Hp 2 -2 phenotype (9 women and 6 men) and 4 samples of Hp 1-1 phenotype (3 women and 1 man). The relative content of phenotypes was as follows: 57% of 2 -1 phenotype, 34% of 2 -2 phenotype and 9% of 1-1 phenotype.
The sample designated 'control Hp 2 -2 ' was isolated from serum of one healthy woman (43 years), whose Hp phenotype was identical with that of CDG patient.
Two blood samples obtained from the girl suf fering from the congenital disorder of glycosyla tion (Midro et al., 1996) were kindly provided by Prof. A. Midro (Bialystok Medical Academy). The patient was 14 years old at the moment of the first blood collection, and this haptoglobin sample was designated 'CDG-Hp(1)'. The second sample was taken one year later and designated 'CDG-Hp(2)'. Hp phenotype was determined as 2 -2 (FerensSieczkowska et al., 1999).
Haptoglobin isolation
Haptoglobin was isolated from serum samples using affinity chromatography on Sepharosebound monoclonal anti-Hp antibodies (clones Mo 2.36.71.41 and Mo 7.60.65.55) as described earlier (Kzjtnik and Jadach, 1993) . The purity of prepara tions was examined by SDS-PAGE. Only the CDGHp(1) sample contained an impurity, a small amount of haemoglobin (Hb) bound in Hp-Hb complex.
Determination o f Hp phenotype
Hp phenotypes were determined electrophoretically. Electrophoresis was performed in 6 % poly acrylamide gel according to Whitaker (1967) . Af ter electrophoresis the gel was soaked with 0 .1 % horse haemoglobin, and after washing out the ex cess of haemoglobin the peroxidase activity of HbHp complex was visualized with diaminobenzidine and H2 0 2 as substrates. Alternatively, in the sam ples with lower Hp levels, serum proteins were transferred onto nitrocellulose membrane and Hp subunits were detected with goat anti-Hp antibody and anti-goat IgG-HRP conjugate (Sigma).
Isolation o f glycans
Oligosaccharides were released from the tryptic digests of haptoglobin by endoglycosidase treat ment. Lyophilized protein samples (100-500 |ig) were dissolved in 20 |il of 8 m urea in 0.4 m ammo nium bicarbonate pH 7.9, reduced by adding 5 |il of 45 m M dithiothreitol, incubated for 15 min at 50 °C and then carboxymethylated by adding 5 (tl 100 mM iodoacetic acid for 15 min at room temper ature. The mixture was diluted to obtain 1 m urea concentration. Proteins were digested by sequenc ing grade, modified trypsin (Boehringer Mann heim) for 12 hours at 37 °C with a trypsin/protein ratio of 1:20. The resulting peptide pool was puri fied on Eurosil Bioselect 300 C-18 (5 |im) column (250 x 4 mm, Knauer). The trypsin digest mixture was injected onto the column and washed with 2 % acetonitrile in water, containing 0.06% trifluoracetic acid (TFA). Peptides monitored at 215 nm were eluted from the column by 60% acetonitrile, containing 0.052% TFA, then dissolved in 50 |il of 50 mM phosphate buffer, pH 7.8, containing 0.2% SDS. The mixture was boiled for 5 min, and this step was followed by adding a Complete Protease Inhibitor Coctail (Boehringer Mannheim). Then, peptide-N-glycosidase F from Flavobacterium meningosepticum (PNGase, Boehringer Mann heim) was added to obtain a final concentration of 20 U/ml and the mixture was incubated at 37 °C for 40 h. Glycans were separated from peptides on the C-18 column. The void-volume fractions con taining sugars were collected and dried. Samples containing free oligosaccharides were then puri fied on a GlycoSep H column (100 x 3 mm, Ox ford GlycoSciences). The column was washed with 3% acetonitrile in water, containing 0.05% TFA and eluted with 30% of acetonitrile, containing 0.05% TFA. Oligosaccharide containing fractions were monitored at 2 0 0 nm, collected and dried.
Fluorescence labelling o f glycans
The reducing ends of the oligosaccharides were fluorescently labelled with 2 -aminobenzamide (2 -AB) (Bigge et al., 1995) by the use of a 2-AB Sig nal Labelling Kit (Oxford GlycoSciences) and stored at -20 °C.
Chromatographic separations o f labelled glycans
Oligosaccharide fractionation was performed by HPLC on a Knauer apparatus with a Shimadzu RF-551 fluorescence detector with detection at l raax excitation=330 nm and Xmax emission^ 420 nm. The 2-AB glycan derivatives were sepa rated on an anion exchange GlycoSep C column (100 x 3 mm, Oxford GlycoSciences). Then, frac tions containing neutral, monosialylated, disialylated and trisialylated structures were separated on a normal-phase amide column (GlycoSep N, 250 x 4.6 mm, Oxford GlycoSciences). Gradient conditions were used with a low salt solvent sys tem (LSSS) as described by Guile et al. (1996) . The total run time was 110 min and the column was maintained at 30 °C. The partially hydrolyzed dextran (Oxford GlycoSciences), labelled with 2-AB was used as an external standard and ex pressed in glucose units (GU). Fractions contain ing oligosaccharides were collected, dried, redis solved in a minimal volume (up to 6 (il) of water and injected onto a GlycoSep H column. Glycans were eluted with a 10-30% acetonitrile gradient containing 0.1% TFA, following manufacturer's protocol (GlycoSep™ Oxford GlycoSystem in structions, 1995) . Fractions containing oligosaccha rides were desalted and dried. Table I presents the specificity and concentra tion of exoglycosidases (Oxford GlycoSciences, except of a-mannosidase from X. manihoti, which was purchased from New England Biolabs) used in sequential digestions. Before glycosidase treat ment, purified and fluorescently labelled glycans (0.1-2 nmol of each) were dissolved in 100 m M so dium citrate-phosphate buffer, pH 4.5, containing 100 m M NaCl and 0.2 m M ZnCl2, then the first ex- oglycosidase was added to obtain a final concen tration as described in Table I and a total volume of 30-40 |jl1. After 24-72 h of incubation at 37 °C the reaction was stopped by filtration through a 5 kDa membrane (Ultrafree MC, Millipore), and the membrane was rinsed with 1 0 0 [il of water. The first and second filtrates were combined. A small aliquot from the filtrate (usually about 1 / 6 of total volume) was dried on a rotary evaporator, redissolved in 10 |jl of 70% acetonitrile in water (v/v) and injected onto a GlycoSep N column. The glucose unit (GU) values of glycans were deter mined by comparing their retention times with the external standard (GlycoSep™ Oxford GlycoSystem instructions, 1995). The rest of the filtrate con taining about 5/6 of the total digested glycan was dried, dissolved in water and the next enzyme was added to obtain the required concentration of the exoglycosidase in 30-40 ^1 of total volume.
Exoglycosidase sequencing
Results and Discussion
Four preparations of haptoglobin, derived from pooled 'healthy' human sera, 'healthy' control in dividual of 2 -2 phenotype and two samples from CDG patient were digested with trypsin prior to the endoglycosidase treatment, to increase the efficiency of oligosaccharide release. Direct en doglycosidase digestion of native haptoglobin re sulted in incomplete release of glycans, as under mild reducing conditions the accessibility of gly cans of highly polimeric Hp 2-1 and Hp 2 -2 molecules for the enzyme was limited. Complete pool of released glycans was labelled with 2-AB and purified from peptide fragments on GlycoSep FI column using HPLC system.
The content o f neutral and charged structures in Hp glycans
2-AB-labelled haptoglobin glycans were sepa rated using ion exchange chromatography on the GlycoSep C column. As shown in Fig. 1 , separated peaks were obtained, corresponding to neutral and charged glycans, containing from one to four sialic acid molecules per oligosaccharide chain. The percentage content of particular neutral and charged structures was calculated from the area under appropriate peaks.
We have found high difference in neutral oligo saccharide content among examined haptoglobin preparations. In control Hp from pooled sera the amount of neutral glycans was low, calculated as 2.6%. The content of neutral structures was higher in 'healthy' individual Hp (control Hp 2 -2 ) and reached 13.5%. A high abundance of neutral car bohydrates was found in the first haptoglobin sam ple from the CDG patient, CDG-Hp(1), as the un charged structures comprised almost 90% of 2-AB labelled derivatives. The content of asialoglycans found in CDG-Hp(2) isolated from the blood sam ple taken one year later, was significantly lower and similar to those in control Hp 2 -2 .
Because of such differences in the uncharged structures amount it seemed to be convenient to calculate the relative content of particular sialylated structures as the percentage of total charged haptoglobin glycans. These results are shown in Table II . In all four examined Hp preparations gly cans containing two sialic acid residues were the dominant charged fraction. In both 'healthy con trol' preparations this fraction contained about 60% of charged glycans. The difference in the content of mono-and trisialylated chains reached several percent. As much as about 75% of oligo saccharide chains of normal haptoglobin were of biantennary structure, triantennary glycans were less abundant (slightly less than 25%). Nilsson et al. (1981) reported on glycan structures of 1-1 Hp and claimed that the content of bi-and trianten nary structures was equal. The discrepancy of our results towards that study could suggest possible dependence of the glycosylation on Hp phenotype. In our Hp pool the 1-1 phenotype constituted only 9% of all serum samples. This amount re flected the occurence of this phenotype in the pop ulation, but its influence on the values obtained in our study was less significant.
The content of highly branched tetrasialylated structures in both healthy controls did not exceed 1%.
The content of particular charged chains in CDG patient haptoglobins has shown some differ ence towards controls. In the first sample, CDGHp(1), the content of bisialylated glycans was ele vated to 70% and the content of trisialylated oli gosaccharides was significantly decreased. The tetrasialylated form was undetectable. In the se cond Hp preparation obtained from the blood sample taken after one year, CDG-Hp(2), the content of particular charged oligosaccharides re sembled the normal pattern; only the slight increase in tetrasialylated forms was found.
The pattern o f sialylated glycans o f healthy controls and CDG patient haptoglobins
Fractions of mono-, bi-and trisialylated glycans of all haptoglobin preparations collected after GlycoSep C column were further analysed on the GlycoSep N column.
The chromatographic profiles of sialylated structures were similar when both control hapto-globin preparations were compared as well as when CDG-Hp samples were compared towards controls. Among monosialylated oligosaccharides of control-pooled Hp, 8.22 GU glycan was domi nant comprising 81.5% of this fraction. The 9.43 GU glycan constituted 72.3% of bisialylated gly cans of the same haptoglobin preparation. Among trisialylated glycans of pooled Hp two structures were comparably abundant; the 11.1 GU glycan constituted 47.4% and the 11.56 GU glycan 38.7%. The only difference found in control Hp 2 -2 sam ple was the decreased content of 11.56 GU glycan towards the 11.1 GU one.
The dominant glycans of both CDG-Hp samples showed the same GU values as the control Hp oli gosaccharides and their percentage content also did not differ from the control samples. The rela tive amounts of trisialylated glycans in CDG-Hp samples resembled the control Hp 2 -2 rather than control pooled-Hp, so this difference could be due to Hp phenotype rather than to the disease. Any way, in the chromatographic profiles of charged CDG-Hp glycans slight alterations could be ob served. These concern the increase in one of mo nosialylated fractions in CDG-Hp(2) sample, and the increased heterogeneity and the appearance of the small additional peak in trisialylated glycans of low retention time, also in both CDG-Hp sam ples. In transferrin glycan sequences no significant difference was described in CDG I patients (Iourin et al., 1996) . Our observations indicate, that also in haptoglobin the main abnormality on the glycosylation pathway lies in incomplete occu pation of glycosylation sites.
Sequencing o f dominant haptoglobin glycans
Sequences of four dominant glycans, constitut ing 75% oligosaccharides of haptoglobin obtained from pooled sera of healthy people, were deter mined. Calculated GU values (Guille et al., 1996; GlycoSep™ Oxford Glycosystem instructions, 1995) were used for predicting the structure and designing the strategy for sequential digestion. Proposed structures of sequenced oligosaccharides and their relative content in the total pool of con trol haptoglobin glycans are presented in Table III. 8.22 GU glycan. According to its GU value this glycan was supposed to be the biantennary with only one arm sialylated. The purpose of the se quential analysis was to establish which arm was sialylated and what was the type of sialic acid link Table III age. The digestion was started from the sialic acid lacking arm. The treatment with galactosidase ß 1-4 resulted in 0.86 GU decrease of hydrody namic volume of the reaction product, which cor responded to the loss of one galactose residue. Next enzyme, hexosaminidase ß 1-2, caused the release of one N-acetylglucosamine residue giving 7.05 GU product. This oligosaccharide was resis tant to specific a 1-3-mannosidase indicating, that a 1-3 linked mannose was substituted with the succeeding sugar and not accessible for the en zyme digestion. The 7.05 GU glycan was also resis tant for a 2 -3 sialidase. This proved that the sialic acid was bound to the hydroxyl group of sixth car bon of galactose. Sequential digestion of the gly can with unspecific a 2-3,6 sialidase followed by the treatment with ß-galactosidase and unspecific hexosaminidase led to a 4.29 GU product, ob tained by the release of sialic acid, galactose and N-acetylglucosamine. This value was consistent with reported by Guile et al. (1996) for 'trimannosyl core' of N-glycans. Further digestion with un specific mannosidase 1-2,3,6 led to a release of two mannose residues; the obtained 2.45 GU gly can was identical in its retention time with mannochitobiosyl core glycan. 9.43 GU glycan. The GU value for this glycan was close to the values reported for biantennary structures sialylated at both arms. The glycan was resistant to a 2 -3 specific sialidase digestion, indi cating that both sialic acid residues are bound by a 2 -6 linkage. Sequential digestion with unspecific sialidase, galactosidase ß l-4 , hexosaminidase ß 1-2,6 and mannosidase a l -2,3,6 resulted in a re lease of two appropriate monosaccharide residues at each step. The final product (2.43 GU) repre sented mannochitobiose trisaccharide.
11.1 GU glycan. The 11.1 GU glycan was the only one susceptible for digestion with a 2 -3 spe cific sialidase. This treatment gave a 0.48 GU decrease of hydrodynamic volume and suggested the loss of one out of three sialic acid residues. The product after galactosidase treatment was re sistant to ß 1-2 hexosaminidase. This indicated that a 2 -3 sialic acid was linked to the third an tenna, on which N-acetylglucosamine was bound to mannose by a 1-4 or a 1 -6 linkage, and not to any outer a 1-2 bound arm. The digestion of the 8.76 GU oligosaccharide obtained as described above with unspecific sialidase released two sialic acid residues (decrease of 2.2 GU); further treat ment with ßl-4 galactosidase resulted in two ga lactose residues release. The next enzyme, hexo saminidase a 1-2 caused the release of two Nacetylglucosamine residues, suggesting that the third undigested N-acetylglucosamine residue was ßl-4 bound. Glycans with N-acetylglucosamine bound to mannose with a 1 -6 linkage are resistant to the latter enzyme. In such a case the release of only one N-acetylglucosamine residue should be expected. The former suggestion was further con firmed by the resistance of obtained 4.77 GU gly can for the digestion with specific a 1 -2,3 mannos idase. At the next step of sequencing, unspecific hexosaminidase released the remaining N-acetylglucosamine residue giving as the result the final product of 4.25 GU, identical with the 'trimannosyl core' of N-glycans.
11.59 GU glycan. Predicted from the theoretical values structure should be triantennary, com pletely sialylated. Resistance for sialidase 2 -3 di gestion indicated that all three sialic acid mole cules were a 2 -6 linked. Unspecific a 2-3,6 sialidase treatment resulted in a decrease of hy drodynamic volume corresponding to 2.81 GU, which indicated for the release of three sialic acid residues. Galactosidase released three galactose molecules from the obtained glycan. The reaction product was then digested with hexosaminidase specific for the ß 1 -2 linkage. The enzyme re leased two N-acetylglucosamine residues like in the case of described above glycan 11.1 GU. Simi larly, obtained glycan was resistant to a 1-3 spe cific mannosidase. Finally, the treatment with un specific hexosaminidase and mannosidase mixture resulted in the 2.43 GU product, corresponding to mannochitobiose.
The values obtained in our experiments were in good agreement with values calculated for these structures by general rules reported by Oxford Glycosystem (1995) and also with the values re ported by Guile (1996) . The reported and/or calcu lated values for the same structures were 8.28, 9.44, 11.2 and 11.65 GU, respectively. It should be underlined, that none of these four dominant oli gosaccharides contained fucose. In our previous studies we have found that haptoglobins isolated from both healthy and CDG sera did not react with fucose specific lectin from Alleuria aurantia. Expression of fucosylated oligosaccharides of hap-toglobin increases in cancer and inflamation (Turner et a l, 1995; K^tnik et a l, 1996; Brinkmanvan der Linden et a l, 1998), albeit even in disease it is significantly lower than in other acute phase protein, a r acid glycoprotein (Brinkman-van der Linden et a l, 1998).
Analysis o f neutral compounds
Neutral glycans obtained from all four haptoglo bin preparations were collected after glycoSep C chromatography and analysed further on the Gly coSep N column. In all examined haptoglobin preparations the fractions of uncharged oligosac charides were heterogenous (Fig. 2) Retention time (m in) in Fig. 2 . Structures of lower mass (1-3.38 GU) predominated in both samples of CDG-Hp. Gly can of 7.26 GU, prevailing in control-pooled Hp, was detected also in the other samples, although with relatively decreased abundance. As the sam ples of CDG-Hp glycans were collected in trace amounts, their further analysis was impossible. The only neutral glycan collected after GlycoSep N chromatography in the amount high enough for sequential analysis was the 7.26 GU oligosaccha ride of control-pooled Hp. This glycan was exam ined by exoglycosidase digestion. The glycan ap peared to be resistant to the treatment with galactosidase, hexosaminidase and mannosidase, as the retention times after enzyme treatment were not shifted. Therefore we were not able to determine the structure with enzymatic digestion followed by chromatographic separation and we can only speculate on the nature and origin of this and other low retention time carbohydrate deriva tives. It is possible that the main, neutral glycan contained modified sugars which were resistant to exoglycosidases used in our experiments. There should be also considered that some of uncharged compounds of CDG-Hp(1) could be the result of partial glycation of haemoglobin. The haemoglobin contamination of CDG-Hp(1) re sulted from the presence of tight Hb-Hp complex in the patient plasma sample, which could not be dissociated under isolation conditions (FerensSieczkowska et a l, 1999).
In our previous studies we have found, that hap toglobin of the CDG patient partially lacks oligo saccharide chains (Ferens-Sieczkowska et a l, 1999). About 50% of its ß subunits has all four glycosylation sites occupied, about 30% lacks one out of four and 2 0 % lacks two out of four glycans. Our present study indicates, that the structure of oligosaccharide chains attached to the ß subunit is very similar to that observed in healthy human Hp. Slight difference was found in the relative content of mono, bi, tri, and tetrasialylated structures in Hp obtained from 14-year-old CDG patient, how ever, the sample taken one year later shown the oligosaccharide content similar when compared to the control Hp samples. So far, the information on the glycosylation patterns in the time course of the disease is limited. The only report comparing gly cosylation of several glycoproteins in almost 50 pa tients revealed, that the level of glycoproteins, sig nificantly decreased in early childhood, became normal later. Patients differed in respect to the level of glycosylation defects, and defective glycoforms were more frequent in younger patients (Stibler et al., 1998) . Thus it is possible, that the change of glycans profile reported in this work could be explained by general stabilisation of the CDG symptoms with age.
Concluding, we have characterised glycosylation of haptoglobin obtained from healthy human sera, and defined the relative content and the sequence of dominating glycans. We have also shown, that alterations in glycan composition, concerning the relative amount of a 2 -3 bound terminal sialic acid, could be dependent on the phenotype of this glycoprotein. It has been pointed out as well, that the structure of dominant oligosaccharides of hap toglobin isolated from the serum of CDG type I patient does not differ from the control structures and the differences in the content and profiles of oligosaccharides concern the relatively less abun dant fractions.
